J Korean Diabetes.  2021 Dec;22(4):268-273. 10.4093/jkd.2021.22.4.268.

2021 Korean Diabetes Association Clinical Practice Guidelines for Diabetes: Diabetic Kidney Disease

• Kim NH

• KMID: 2526210
• DOI: http://doi.org/10.4093/jkd.2021.22.4.268

Abstract

Diabetic kidney disease is one of the most serious complications of type 2 diabetes and a leading cause of end-stage kidney disease. Recently, the Korean Diabetes Association released a new version of clinical practice guidelines including substantial changes in the management of diabetic kidney disease. Of note, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists are now the preferred glucose-lowering agents for reduced glomerular filtration rate or albuminuria. Convincing evidence from cardiovascular or renal outcome trials supports the recommendation of those drugs. This review summarizes the results of recent clinical studies on diabetic kidney disease and explains new clinical recommendations based on them.

Keyword

Clinical guidelines; Diabetic kidney disease; Hypoglycemic agent

Reference

1.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guide-line for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013. 3:1–150.

2.Brenner BM., Cooper ME., de Zeeuw D., Keane WF., Mitch WE., Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001. 345:861–9.

3.Lewis EJ., Hunsicker LG., Clarke WR., Berl T., Pohl MA., Lewis JB, et al. Renoprotective effect of the angioten-sin-receptor antagonist irbesartan in patients with Nephropathy due to type 2 diabetes. N Engl J Med. 2001. 345:851–60.

4.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000. 355:253–9.

5.Parving HH., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001. 345:870–8.

6.Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009. 361:40–51.

7.ONTARGET Investigators., Yusuf S., Teo KK., Pogue J., Dyal L., Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008. 358:1547–59.

8.Wanner C., Inzucchi SE., Lachin JM., Fitchett D., von Eynat-ten M., Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016. 375:323–34.

9.Wiviott SD., Raz I., Bonaca MP., Mosenzon O., Kato ET., Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019. 380:347–57.

10.Heerspink HJL., Stefánsson BV., Correa-Rotter R., Chertow GM., Greene T., Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020. 383:1436–46.

11.McGuire DK., Shih WJ., Cosentino F., Charbonnel B., Cherney DZI., Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Car-diol. 2021. 6:148–58.

12.Zelniker TA., Wiviott SD., Raz I., Im K., Goodrich EL., Bonaca MP, et al. SGLT2 inhibitors for primary and second-ary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019. 393:31–9.

13.Neuen BL., Young T., Heerspink HJL., Neal B., Perkovic V., Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019. 7:845–54.

14.Mann JFE., Ørsted DD., Brown-Frandsen K., Marso SP., Poulter NR., Rasmussen S, et al. Liraglutide and renal Outcomes in type 2 diabetes. N Engl J Med. 2017. 377:839–48.

15.Gerstein HC., Colhoun HM., Dagenais GR., Diaz R., Lakshmanan M., Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. 394:121–30.

16.Kristensen SL., R⊘rth R., Jhund PS., Docherty KF., Sattar N., Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019. 7:776–85.

17.Muskiet MHA., Tonneijck L., Huang Y., Liu M., Saremi A., Heerspink HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018. 6:859–69.

18.Tuttle KR., Lakshmanan MC., Rayner B., Busch RS., Zim-mermann AG., Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and mod-erate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. 6:605–17.